




Regulatory and reimbursement issues aside, for a younger patient (<65 years old) with primary BRAF V600E wild-type melanoma for whom you are recommending adjuvant therapy, what is your usual choice of treatment?




Regulatory and reimbursement issues aside, for a younger patient (<65 years old) with primary BRAF V600E-mutant melanoma for whom you are recommending adjuvant therapy, what is your usual choice of treatment?




Do you consider PD-L1 levels when attempting to decide on first-line therapy for patients with metastatic melanoma?




What is your usual first-line treatment for an asymptomatic, clinically stable younger patient with BRAF-mutant metastatic melanoma and PD-L1 expression of 0%?




What is your usual first-line treatment for a symptomatic younger patient with extensive BRAF-mutant metastatic melanoma?




What is your usual first-line treatment for an asymptomatic, clinically stable younger patient with BRAF wild-type metastatic melanoma?



What is your usual first-line treatment for a symptomatic younger patient with extensive BRAF wild-type metastatic melanoma?



What is your usual initial treatment approach for an asymptomatic younger patient with BRAF wild-type metastatic melanoma including multiple bilateral brain metastases?



What is your usual initial treatment approach for an asymptomatic younger patient with BRAF-mutant metastatic melanoma including multiple bilateral brain metastases?

